Technical Analysis for CALA - Calithera Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Historical CALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Death Cross | Bearish | 2.67% | |
| Bullish Engulfing | Bullish | 2.67% | |
| Lower Bollinger Band Walk | Weakness | 2.67% | |
| Lower Bollinger Band Touch | Weakness | 2.67% | |
| Oversold Stochastic | Weakness | 2.67% | |
| Lower Bollinger Band Walk | Weakness | 6.38% | |
| Lower Bollinger Band Touch | Weakness | 6.38% | |
| Oversold Stochastic | Weakness | 6.38% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/10/2020
- Sector: Healthcare
- Industry: Biotechnology
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Cancer Oncology Treatment Of Cancer Solid Tumors Tumor Lymphoma Multiple Myeloma Targeted Therapy Hematology Anatomical Pathology Lymphomas Leukemias Phosphoinositide 3 Kinase Inhibitor
Medicine Biopharmaceutical Cancer Oncology Treatment Of Cancer Solid Tumors Tumor Lymphoma Multiple Myeloma Targeted Therapy Hematology Anatomical Pathology Lymphomas Leukemias Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.18 |
| 52 Week Low | 2.45 |
| Average Volume | 643,367 |
| 200-Day Moving Average | 5.36 |
| 50-Day Moving Average | 5.29 |
| 20-Day Moving Average | 5.09 |
| 10-Day Moving Average | 4.93 |
| Average True Range | 0.26 |
| ADX | 15.6 |
| +DI | 16.81 |
| -DI | 20.99 |
| Chandelier Exit (Long, 3 ATRs ) | 4.76 |
| Chandelier Exit (Short, 3 ATRs ) | 5.42 |
| Upper Bollinger Band | 5.53 |
| Lower Bollinger Band | 4.65 |
| Percent B (%b) | 0.39 |
| BandWidth | 17.29 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.13 |
| MACD Histogram | -0.0129 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.36 | ||||
| Resistance 3 (R3) | 5.33 | 5.17 | 5.30 | ||
| Resistance 2 (R2) | 5.17 | 5.08 | 5.19 | 5.28 | |
| Resistance 1 (R1) | 5.09 | 5.03 | 5.13 | 5.12 | 5.26 |
| Pivot Point | 4.93 | 4.93 | 4.96 | 4.95 | 4.93 |
| Support 1 (S1) | 4.85 | 4.84 | 4.89 | 4.88 | 4.74 |
| Support 2 (S2) | 4.69 | 4.79 | 4.71 | 4.72 | |
| Support 3 (S3) | 4.61 | 4.69 | 4.70 | ||
| Support 4 (S4) | 4.64 |
